Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (May 2019)
27 slides from Genetic Technologies's investor presentation, May 2, 2019
Slide 1: Forward looking statements
Forwardlookingstatements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of
Slide 2: Who we are
Whoweare Research and Development leader in the genomics sector • Developing and commercialising a suite of genetic risk assessment products to prevent morbidity and mortality across a range of diseases 20 years experience bringing genomics products to market • Progressive R&D and commercialisation
Slide 3: Our vision
Our • vision To improve health outcomes for people around the world by providing individuals and their physicians with the risk assessment tools to develop personalised health management plans for early detection and treatment of chronic disease To continually strive to maintain our standing as a gl
Slide 4: Our vision
Our vision . To improve health outcomes for people around the world by providing individuals and their physicians with the risk assessment tools to develop personalised health management plans for early detection and treatment of chronic disease To continually strive to maintain our standing as a gl
Slide 5: Our genetic test predicts a woman's risk of developing breast cancer
Ourgenetictestpredictsawoman’srisk ofdevelopingbreastcancer BREVAGenplus® is a first-to-market, clinically validated genetic risk assessment for non-hereditary (sporadic) breast cancer Simple cheek swab that helps determine a woman’s risk of developing breast cancer First test of its kind to be clin
Slide 6: Precision medicine
Precisionmedicine 1 in eight women will get breast cancer in their lifetime Screening programs that test all women at the same intervals overscreening 7 women and underscreening 1 woman • • will be Our risk assessment test offers health policy regulators and clinicians the potential for more efficie
Slide 7: Early detection = better outcomes
Earlydetection=betteroutcomes 5 year survival rates dramatically improve when breast cancer is diagnosed before spreading to other parts of the body 8 https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
Slide 8: Early diagnosis = less expensive treatment
Early diagnosis =lessexpensive treatment Stage I $ 55,000 First year treatment costs for Stage II $103,000 breast cancer Stage III and IV $127,000 USD, study based on US patients, 2003-2010 9 https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0207993.t001
Slide 9: Targeted screening and prevention
Targetedscreening andprevention Screening More frequent mammograms or MRIs BREVAGenplus® enables the targeting of limited resources to women who are most likely to develop breast cancer. Medication Selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) Lifestyle Weight loss, al
Slide 10: GTG's enhanced breast cancer test covers 95% of women
GTG’senhancedbreast covers95%ofwomen cancer test Only 5% of women with breast cancer have a pathogenic variant, such as BRCA • 85% of women have no family history of breast cancer 10% have a family history but no pathogenic variants, such as BRCA • 95%of women Our test covers 12 * Pathogenic variant
Slide 11: GTG has developed a world-first polygenic risk test for colon cancer
GTGhasdevelopedaworld-first polygenicrisktest for colon cancer Risk stratification enables precision screening and Easy-to-use test solves personalised prevention the compliance problem Clinically actionable results 5-year, 10-year and lifetime risk Informs screening and health monitoring for those
Slide 12: Collaboration with world-leading partners
Collaborationwith world-leading partners
Slide 13: Development of Commercialization Strategy with TGen
Development of Commercialization Strategy with TGen MOU Signed GTG and TGen will cooperate in the development of a commercialisation strategy and infrastructure development for a suite of polygenic risk tests to be made available in the US market. The collaboration will be wide in scope covering: •
Slide 14: Translational Genomics Research Institute (TGen): Collaborative Background
Translational Genomics Research Institute (TGen): Collaborative Background Network Areas of Disease Focus - - - - - Oncology Neurology Rare Childhood Disorders Diabetes Infectious Disease - - - - - Est. 2002 Non-profit (501c3) Patient-focused clinical & basic research Pioneers in precision genomic m
Slide 15: The Distribution Channel
The Distribution Channel The TGen collaboration opens up a number of potential distribution channels: I. Major US Healthcare Systems Distribution II. National Distribution opportunity: Health care system test availability Cancer Centers opportunity: Testing of cancer patients an family members III.
Slide 16: The Distribution Channel
The Distribution Channel V. Disease consortiums Distribution opportunity: Clinical studies VI. State Government validity and clinical utility Distribution opportunity: Public health department “endorsement;” Public policy; Clinical utility studies VII. Federal Government Distribution opportunity: Re
Slide 17: The TGen Clinical Laboratory
The Tgen Clinical Laboratory • • • • • Founded in 2011 CLIA certified in 2013 CAP certified 2014 Provided some of the world’s first clinical studies for personalized cancer treatment Spun out from TGen in 2014, provides commercial access to personalized cancer treatment via genomic profiling of DNA
Slide 18: Collaboration is a key market advantage
Collaborationisakeymarket advantage The University of Melbourne • Australia’s peak research-intensive institution, ranked 32nd globally Our • collaboration with The University of Melbourne was awarded an NHMRC grant Research investigation to assess the improvement in breast cancer risk prediction us
Slide 19: Research into clinical applications
Research into clinical applications GTG has an agreement in place with Memorial Sloan Kettering (MSK) and University of Cambridge • The research is led by Mark E. Robson, MD, Chief of Breast Medicine Service, Memorial Sloan Kettering MSK is the world’s oldest and largest cancer treatment and researc
Slide 20: Other key partnerships
Other key partnerships Ohio State University (Columbus, Ohio) • Research collaboration exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations Led by Amanda Toland, Director of Clinical Genetics and a leader in the field of breast cancer risk assessment • N
Slide 21: Intellectual property is our advantage
Intellectualpropertyisouradvantage GTG has a strong patent portfolio covering the breast cancer risk assessment test 5 Patents granted in China 5 Patents granted in the US • Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and • Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three
Slide 22: Scientific authority
Scientific authority Dr. Richard Allman, Chief Scientific Officer • • Strong publication record in genetic epidemiology across multiple disease categories Collaboration for peer review and statistical validation BSc Microbiology, PhD Microbiology (Flow Cytometric Analysis of Bacteria) Honorary Fello
Slide 23: Hainan Medical Pilot Zone
HainanMedicalPilotZone GTG has established its Asian operations with the formation of Genetic Technologies HK and Hainan Aocheng Genetic Technologies • • Part of the Hainan Free Trade Zone Initiative Best-in-class medical care, physicians, treatments, technology and cutting-edge medical product deve
Slide 24: GTG's approach aligns with Healthy China 2030
GTG’sapproachalignswithHealthy China2030 Healthy China 2030 is the Chinese Central Government’s comprehensive healthcare policy for 1.5 billion people • • Disease prevention is a means of controlling costs Chinese government can enforce compliance with preventive healthcare protocols GTG tests can b
Slide 25: Next Steps in China
NextStepsinChina Develop collaborative relationships Deliver the benefits of genetic screening • • • • Clinical validation Regulatory approval Commercial channels • Go-to-market plan for additional genetic screening tests Engagement with key opinion leaders • • Collaboration with organisations Chine
Slide 26: Thank you
Thank you Paul Kasian Chairman and CEO paul.kasian@gtglabs.com www.gtgcorporate.com 28
Slide 27: Thank you
Genetic Technologies Thank you Paul Kasian Chairman and CEO paul.kasian@gtglabs.com www.gtgcorporate.com
Genetic Technologies — Investor Presentation (May 2019) on 6ix